Ironwood Pharmaceuticals - IRWD Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IRWD shares.
View IRWD analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12 month price targets for Ironwood Pharmaceuticals' stock. Their IRWD share price forecasts range from $13.00 to $16.00. On average, they expect the company's stock price to reach $14.67 in the next twelve months. This suggests a possible upside of 39.8% from the stock's current price.
View analysts price targets for IRWD or view top-rated stocks among Wall Street analysts.

Ironwood Pharmaceuticals' stock was trading at $12.39 at the beginning of the year. Since then, IRWD stock has decreased by 15.3% and is now trading at $10.49.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our IRWD earnings forecast.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) posted its quarterly earnings results on Thursday, February, 16th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by $0.01. The biotechnology company earned $107.20 million during the quarter, compared to analysts' expectations of $108.23 million. Ironwood Pharmaceuticals had a trailing twelve-month return on equity of 30.49% and a net margin of 42.64%. The company's quarterly revenue was down 8.5% on a year-over-year basis. During the same period in the prior year, the business earned $0.27 EPS.

ETFs with the largest weight of Ironwood Pharmaceuticals (NASDAQ:IRWD) stock in their portfolio include First Trust Nasdaq Pharmaceuticals ETF (FTXH), LeaderShares Activist Leaders ETF (ACTV), Invesco Dynamic Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Invesco S&P SmallCap Health Care ETF (PSCH), Pacer US Small Cap Cash Cows 100 ETF (CALF), ETC 6 Meridian Small Cap Equity ETF (SIXS) and SPDR S&P Biotech ETF (XBI).

Ironwood Pharmaceuticals updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $420.00 million-$435.00 million, compared to the consensus revenue estimate of $426.76 million.

7 employees have rated Ironwood Pharmaceuticals Chief Executive Officer Mark Mallon on Glassdoor.com. Mark Mallon has an approval rating of 93% among the company's employees. This puts Mark Mallon in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ironwood Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), NIC (EGOV), Athabasca Oil (ATH), Allergan (AGN), Aegean Marine Petroleum Network (ANW), Micron Technology (MU) and Starbucks (SBUX).

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include LSV Asset Management (5.17%), Renaissance Technologies LLC (2.85%), Millennium Management LLC (2.60%), Dimensional Fund Advisors LP (2.39%), Victory Capital Management Inc. (1.88%) and Geode Capital Management LLC (1.64%). Insiders that own company stock include Alexander J Denner, Andrew Davis, Jason Rickard, Julie Mchugh, Kelly Macdonald, Mark G Currie, Marla L Kessler, Michael Shetzline, Ronald Silver, Thomas A Mccourt and Timothy M O'reilly.
View institutional ownership trends.

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IRWD stock can currently be purchased for approximately $10.49.

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a market capitalization of $1.62 billion and generates $410.60 million in revenue each year. The biotechnology company earns $175.07 million in net income (profit) each year or $0.97 on an earnings per share basis.

The company employs 219 workers across the globe.

Ironwood Pharmaceuticals' mailing address is 100 SUMMER STREET SUITE 2300, BOSTON MA, 02110. The official website for the company is www.ironwoodpharma.com. The biotechnology company can be reached via phone at (617) 621-7722, via email at mkaya@ironwoodpharma.com, or via fax at 617-494-0480.